Peptide therapies vary widely in evidence, FDA status, manufacturing standards, dosing, potential benefits and risks. A peptide should not be considered safe simply because it is described as “natural” or sold online. This guide explains why physician evaluation, accurate diagnosis and product-specific evidence matter.
FDA-approved drugs undergo agency review for their approved indications. Compounded drugs are not FDA approved, and FDA does not review compounded products for safety, effectiveness, or quality before they are marketed. Compounding can serve an important medical need in appropriate circumstances, but it is not equivalent to FDA approval.
There is no universal peptide side-effect list. Risks can include pharmacologic effects of the active substance, injection-site reactions, hypersensitivity, interactions, dosing errors, sterility or quality problems, and peptide-related impurities. FDA has specifically identified potential safety concerns for several bulk peptide substances used or proposed for compounding, including BPC-157, CJC-1295 and ipamorelin.
Testing is individualized rather than automatic. Depending on symptoms, history and the therapy being considered, a physician may evaluate metabolic health, glucose regulation, thyroid function, nutritional status, relevant hormone pathways, liver or kidney function, and other clinical factors. Testing should answer a medical question and help guide safe treatment.
Patients should understand the intended indication, strength of human evidence, FDA status, expected benefit, known and uncertain risks, alternatives, monitoring plan, source of the medication, and what symptoms should prompt medical attention. Claims such as “research grade,” “pharmaceutical grade,” or “high purity” do not by themselves establish that a product is approved, effective, or appropriate for human use.
No. Compounded drugs are not FDA approved. Their legal availability also depends on the particular substance and applicable federal and state requirements.
No. Online availability is not evidence of FDA approval, clinical effectiveness, product quality, or appropriateness for an individual patient.
Not every patient needs the same tests. Laboratory evaluation should be selected based on medical history, symptoms, examination, medications and the treatment under consideration.
Read our guides to Peptide Therapy, BPC-157, CJC-1295 and Ipamorelin, Sermorelin, and Tesamorelin.
The comprehensive initial physician evaluation is $450, with follow-up physician visits at $250. Recommendations are individualized and a prescription is not guaranteed.
